Zobrazeno 1 - 10
of 89
pro vyhledávání: '"C, Trifan"'
Autor:
David Liu, Rosanne Welcher, Stephen Chan, Ling-Ming Tseng, Cristina Saura, Ovidiu C. Trifan, Guan Xing, Lajos Pusztai, Christine E. Horak
PDF file - 65K, Summary of gene models
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f7fda185af754db6116d5b6f1c0e4e8
https://doi.org/10.1158/1078-0432.22450680
https://doi.org/10.1158/1078-0432.22450680
Autor:
David Liu, Rosanne Welcher, Stephen Chan, Ling-Ming Tseng, Cristina Saura, Ovidiu C. Trifan, Guan Xing, Lajos Pusztai, Christine E. Horak
PDF file - 78K, Logistic regression: βIII-tubulin, other β-tubulin isoforms, TACC3 and CAPG (randomized patients with non-missing pCR and biomarker expressions)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52fcdc82b28c58ff629292513e2e3280
https://doi.org/10.1158/1078-0432.22450683
https://doi.org/10.1158/1078-0432.22450683
Autor:
David Liu, Rosanne Welcher, Stephen Chan, Ling-Ming Tseng, Cristina Saura, Ovidiu C. Trifan, Guan Xing, Lajos Pusztai, Christine E. Horak
Purpose: Predictive biomarkers offer the potential to improve the benefit:risk ratio of a therapeutic agent. Ixabepilone achieves comparable pathologic complete response (pCR) rates to other active drugs in the neoadjuvant setting. This phase II tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::024d53a9e8484facc206649ba3ccda7c
https://doi.org/10.1158/1078-0432.c.6521997.v1
https://doi.org/10.1158/1078-0432.c.6521997.v1
Autor:
David Liu, Rosanne Welcher, Stephen Chan, Ling-Ming Tseng, Cristina Saura, Ovidiu C. Trifan, Guan Xing, Lajos Pusztai, Christine E. Horak
PDF file - 77K, Baseline characteristics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f3684300d02136c0d708c61c80ce22d
https://doi.org/10.1158/1078-0432.22450689.v1
https://doi.org/10.1158/1078-0432.22450689.v1
Autor:
David Liu, Rosanne Welcher, Stephen Chan, Ling-Ming Tseng, Cristina Saura, Ovidiu C. Trifan, Guan Xing, Lajos Pusztai, Christine E. Horak
PDF file - 50K, Correlation between βIII-tubulin IHC (Saura et al. manuscript in preparation) and mRNA expression data. *Median cut-off used to determine high versus low βIII-tubulin mRNA expression. IHC, immunohistochemistry.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d53e99e3f41026ca4610db164fc4faf
https://doi.org/10.1158/1078-0432.22450695
https://doi.org/10.1158/1078-0432.22450695
Autor:
David Liu, Rosanne Welcher, Stephen Chan, Ling-Ming Tseng, Cristina Saura, Ovidiu C. Trifan, Guan Xing, Lajos Pusztai, Christine E. Horak
PDF file - 68K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0ffd5b5210d5c9cd6b4d0d8982794b7
https://doi.org/10.1158/1078-0432.22450692.v1
https://doi.org/10.1158/1078-0432.22450692.v1
Autor:
David Liu, Rosanne Welcher, Stephen Chan, Ling-Ming Tseng, Cristina Saura, Ovidiu C. Trifan, Guan Xing, Lajos Pusztai, Christine E. Horak
PDF file - 94K, RNA, cRNA and GeneChip quality metrics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efbaf1bbc05be161c7c7930c90b9404f
https://doi.org/10.1158/1078-0432.22450686
https://doi.org/10.1158/1078-0432.22450686
Autor:
Marwan Fakih, Davendra P. Sohal, Navid Hafez, Jordan D. Berlin, Kimberly Hari, Ovid C. Trifan
Publikováno v:
Cancer Research. 83:CT249-CT249
Background: TOS-358 is an orally available, highly selective covalent inhibitor of PI3Kα capable of achieving a deep and durable inhibition of PI3K-AKT signaling with virtually no off-target effects. In patient-derived xenograft models, TOS-358 has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::567ee0d41731642f93c32709326ff672
https://doi.org/10.1158/1538-7445.am2023-ct249
https://doi.org/10.1158/1538-7445.am2023-ct249
Publikováno v:
European Urology. 83:S1969
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f21e7814954378bbda277fc46c7bc65c
https://doi.org/10.1016/s0302-2838(23)01405-7
https://doi.org/10.1016/s0302-2838(23)01405-7
Autor:
Wei Wei, Amit Mahajan, Michael E. Hurwitz, Susan M. Kaech, Ovidiu C. Trifan, Barbara Johnson, William Damsky, Dijana Djureinovic, Sarah A. Weiss, Lin Zhang, Gail Anderson, Neta Shanwetter Levit, Lucia B. Jilaveanu, Curtis J. Perry, Amanda Ralabate, Daniel Zelterman, Shlomit Jessel, Marcus Bosenberg, Irina Krykbaeva, Harriet M. Kluger, Scott N. Gettinger, Mario Sznol
Publikováno v:
Clin Cancer Res
Purpose: PD-1/PD-L1 inhibitors are approved for multiple tumor types. However, resistance poses substantial clinical challenges. Patients and Methods: We conducted a phase I trial of CD40 agonist APX005M (sotigalimab) and CSF1R inhibitor cabiralizuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bf4bd6fb6ebd68e8249c5eefad14aec
https://europepmc.org/articles/PMC9236708/
https://europepmc.org/articles/PMC9236708/